4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
InflaRx N.V. (IFRX) operates in the Biotechnology industry and is headquartered in Jena, Germany with about 65 employees. Its market capitalization is roughly $304 million. In the fiscal year ended 2025-12-31, IFRX reported $0M in revenue and ($46M) in net income.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Interactive charts & full statements → Open the IFRX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Gross Profit | ($7M) | ($3M) | ($0M) | $0M |
| Operating Income (EBIT) | ($48M) | ($53M) | ($45M) | ($32M) |
| Net Income | ($46M) | ($46M) | ($43M) | ($30M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | ($5M) | $0M | ($2M) | $0M |
| Operating Income (EBIT) | ($7M) | ($13M) | ($10M) | ($13M) | ($13M) |
| Net Income | ($6M) | ($11M) | ($12M) | ($14M) | ($8M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $55M | $76M | $120M | $102M | — |
| Total Liabilities | $14M | $15M | $18M | $14M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IFRX viewer.
About TickerBase · Data methodology & sources